Solving Medicare/Medicaid Insolvency – Part III

We’re discussing the insolvency of Medicare and Medicaid and what needs to be done. Seema Verma, former administrator for the Centers for Medicare and Medicaid Services under President Trump, offers her solutions in a recent article published in The Wall Street Journal.

In Part I we discussed Verma’s solution of a value-based reimbursement model, which is often called capitation payments.  This means payment based on the number of patient lives covered by the physician provider or hospital system. After a fixed payment for each patient, no additional payments are received, regardless of the treatment provided.

In Part II, Verma discussed how to avoid rationing of care by holding providers accountable for both quality and patient outcomes. But there are drawbacks to these practices, which I discussed as well. Furthermore, she discussed how to lower the costs of drugs in the federal 340B Drug Pricing Program, which provides discounted drugs to so-called safety-net providers to help them reduce medication costs for low-income patients. She is concerned about these providers unfairly profiting from not passing along discounts they received.

In Part III, I will address these concerns and others she expresses, and then offer some solutions to the rising costs of Medicare and Medicaid. To begin, I will repeat her last concern:

Verma is concerned about the drugs provided to Medicaid enrollees. The federal 340B Drug Pricing Program provides discounted drugs to so-called safety-net providers to help them reduce medication costs for low-income patients. But she argues providers aren’t required to pass on the discounts when selling medicines to patients and can pocket the profit. To this end, 340B providers have worked to acquire physician-owned clinics and smaller hospitals, allowing them to expand their use of the program and thus their profit and monopoly power.

I would say there are simple solutions to her concerns. First, limit the amount of mark-up these providers can charge for these drugs to a reasonable amount to cover their overhead. The worker’s compensation system in Florida has limited such mark-ups to 20%. With current inflation at 6.5%, perhaps this number needs to be a bit higher, say 25%. On the other hand, physician-owned clinics and smaller for-profit hospitals have been shown to reduce overall healthcare costs, not increase them. Also, when providers can see more profit available, it makes access to healthcare more available. Limited access to healthcare is a major problem with Medicaid patients.

Verma does make a good point concerning surgery. Medicare forces seniors to get surgeries in hospitals. The “Medicare inpatient-only list” outlines the type of procedures that are reimbursable only if done in hospitals. This includes joint replacement surgeries, which are among the most frequent procedures for seniors. Many operations can be safely performed in outpatient centers where the cost is lower and the quality is even higher. Current rules make it harder for outpatient surgery centers to compete with large hospital monopolies, which perform the vast majority of surgeries for Medicare patients. Allowing these same procedures to be performed in outpatient centers would likely cut the cost in half or more.

The Trump administration tried to fix this problem by removing the inpatient-only list, making it clear that medical decisions shouldn’t be made by federal bureaucrats. Unfortunately, the Biden administration reversed this Trump decision, like so many others, with adverse results. The costs for Medicare and seniors have gone up again.

Verma also makes another good point when she says more needs to be done to enforce price-transparency regulations for both payers and hospitals. Transparency allows competition and market forces to be effective in lowering costs. She calls on the president and Congress to work to lower costs and increase quality through market competition to avoid more draconian changes like benefit cuts, increased taxes or higher beneficiary spending.

What are my solutions?

I would say there is another significant way to lower Medicare/Medicaid costs – increase the eligibility requirements. When Medicare was enacted on July 30, 1965, life expectancy was 66.8 years for men and 73.7 for women. That means the average man became eligible for Medicare only 1.8 years before his expected death. The average woman became eligible only 8.7 years before her expected death. That means the government was only picking up the tab for 1.8 and 8.7 years for men and women respectively.

Today the life expectancy of a man is 79.1 years and for women it is 81 years. That means today the government must pay the healthcare expenses of a man for an average of 14.1 years and for a woman 16 years compared to 1.8 years and 8.7 years in 1965. Congress never anticipated such a huge increase in expenses for subsidizing healthcare.

Medicaid eligibility is dependent on economics, not age. Medicaid was originally implemented to cover pregnant women, children, and the elderly and disabled. Income eligibility varied by states. The original eligibility for pregnant women and young children was household income below 133 percent of the federal poverty line (FPL). For school age children it dropped to 100 percent of FPL and for the elderly and disabled to 75 percent of FPL. For working parents, it went down to 25 percent of FPL. Able-bodied adults were ineligible.

All that has changed since the Affordable Care Act (ObamaCare) of 2010. Eligibility was increased to 138 percent of FPL for all enrollees if states opted in. This includes able-bodied adults, who were never originally intended to be eligible. Today, 40 states have opted in including the District of Columbia, while 11 states remain under the old eligibility rules. Medicaid enrollment today is 82.3 million according to the Kaiser Family Foundation. In 2010, just before the passage of ObamaCare, only 54.6 million were enrolled. This huge expansion of Medicaid is a major reason why we are now over $31 trillion in debt.

The solution to the insolvency of Medicare is raising the age of eligibility. There is no reason for the federal government to be picking up most of the tab for seniors for the last 14 years or more of their lives. This was never the original intent of Congress. For Medicaid, the solution is lowering the eligibility levels to their original intent – low-income Americans, pregnant women, young children and the disabled. Covering the healthcare of abled-bodied adults was never the original intent of Congress.  These adults can get a job – there are literally millions of jobs out there looking for people to work and many will provide health insurance. It’s time we decreased the rolls of those who are dependent on the federal government.

These two solutions are simple to explain – but will require compromise by both political parties to achieve. Unfortunately, even discussing solutions has become a weapon in the arsenal of some politicians. This will only change when the American people demand changes to safeguard these important entitlements for the security of their future.

 

Solving Medicare/Medicaid Insolvency – Part II

 

In Part I of this series, we discussed the problem of Medicare/Medicaid insolvency and what might be done to solve this problem. Seema Verma, former administrator for the Centers for Medicare and Medicaid Services under President Trump, offers her solutions in a recent article published in The Wall Street Journal.

Last post Verma suggested the solution is to convert Medicaid to a value-based reimbursement model. The more common term for this type of healthcare is capitation, or payment based on the number of patient lives covered by the physician provider or hospital system. After a fixed payment for each patient, no additional payments are received, regardless of the treatment provided. While Verma argues this will bring down costs, and it will, I argued that this provided the wrong incentives to providers – it encourages them to withhold treatment, especially if it is expensive. (For more on this argument, see Part I.)

A common problem with capitated payments is the rationing of care. Verma addresses this concern today. She argues that to ensure care isn’t rationed, part of the doctor’s reimbursement is tied to quality and patient outcomes. For example, doctors can use part of the capitated payment to cover the costs of home modifications to prevent falls, to provide medically tailored meals for diabetics, or to send a nurse to a patient’s home to administer medications. Unless this expense is in addition to the capitated payments, you can be sure doctors and hospitals are not going to pay for such luxuries.

She goes on to say value-based reimbursement can also be used to address new high-cost medications. If a patient doesn’t show meaningful improvement after taking the medication, the drug manufacturer’s reimbursement would be reduced or not paid at all. But who is going to decide how to define “meaningful improvement?” The answer is the government, not the doctor. This is just rationing by another name.

The same strategy for lowering costs is used in socialized medicine countries. If the government determines the cost of the treatment is not going to result in “meaningful improvement,” the treatment is denied. This may be due to the patient’s age, years of life expectancy, usefulness of the patient to society, or other parameters determined by the government.

Ms. Verma advocates for more competition in America, and that does make sense. Competition always lowers the cost and improves the quality of any service or manufactured product. But that only occurs when there is a level-playing field. As it stands right now, there are broken federal policies that benefit healthcare monopolies and these need to be eliminated. Where healthcare systems enjoy a monopoly, no competition can exist.

Verma says these healthcare monopolies are refusing to be held accountable for quality, to accept value-based contracts, or to negotiate prices with payers, employers and state Medicaid agencies. Perhaps she should consider a Medicaid model based on the highly successful Medicare Advantage plans that allows private insurance companies to compete for seniors in the Medicare system. The results of competition there have lowered premiums and provided additional services to those who enroll. Millions of American seniors now benefit from these plans.

Verma is also concerned about the drugs provided to Medicaid enrollees. The federal 340B Drug Pricing Program provides discounted drugs to so-called safety-net providers to help them reduce medication costs for low-income patients. But she argues providers aren’t required to pass on the discounts when selling medicines to patients, and can pocket the profit. To this end, 340B providers have worked to acquire physician-owned clinics and smaller hospitals, allowing them to expand their use of the program and thus their profit and monopoly power.

 

(For more on this subject, stay tuned for Part III of this series on my next blog.)

Solving Medicare/Medicaid Insolvency – Part I

Medicare and Medicaid are on the road to insolvency. There is no doubt about that among the numbers-crunchers; just among the politicians. It’s long been held that Social Security and Medicare are the “third rails” of politics – if you touch them, you’ll get burned. The recent uproar at the State of the Union address when President Biden falsely accused Republicans of wanting to get rid of these entitlements is just the latest in a long series of attempts to scare seniors into voting for Democrats.

But it is time that the adults in the room had a serious discussion about how to solve the insolvency problem. Seema Verma, former administrator for the Centers for Medicare and Medicaid Services under President Trump, offers her solutions in a recent article published in The Wall Street Journal.

Verma says the Medicare board of trustees has warned that the program is headed for insolvency in as little as six years. Medicaid has become the largest budget item in most states. Medicare and Medicaid collectively are two of the largest contributors to the national debt and will be the largest federal budget item by 2030, according to the Congressional Budget Office (CBO).

What are the solutions?

Verma says the answer to the current challenge doesn’t have to be rationing of care, higher taxes or increased costs for beneficiaries. Instead, she calls on the president to work with Congress to address the programs’ structural problems using common-sense market-based reforms. She believes doing so will help sustain important safety-net programs and improve the healthcare system for all Americans.

She believes the problem is fee-for-service medicine – the long-standing model for most healthcare in our country since health insurance was first introduced to the market. She says this model pays doctors and hospitals for the volume of service they perform with no regard to quality or outcomes. She calls for a change of the Medicare and Medicaid reimbursement schema by moving them toward a value-based reimbursement model. 

In value-based care, instead of getting paid only when a patient gets sick or for rendering a specific treatment, a doctor is prepaid a fixed amount based on the patient’s health status. This payment method is used to cover all the patient’s healthcare-related costs. The prepaid amount creates incentives for the provider to make investments in the type of care that avoids expensive emergency-room visits and hospital stays – at least according to Ms. Verma.

A value-based reimbursement model is another name for capitated payments. This type of reimbursement model has been around a long time since the implementation of managed care in the 1980s. It was first proposed then by large managed care systems as a way to save money. It may accomplish that goal, but at the expense of quality of care. Ms. Verma says this form of reimbursement “creates incentives for the provider to make investments in the type of care that avoids expensive emergency-room visits and hospital stays” – which sounds good on its surface.

But the real incentives this form of payment creates are for doctors and hospitals to withhold treatment. I’d like to believe that doctors will always do what’s in the best interests of the patient, and we usually do, but doctors are also humans and incentives matter. When the doctor can make just as much money writing a prescription or giving a shot as they can doing surgery, which one do you think will be chosen most of the time? To make matters worse, since more doctors than ever are now employed by hospitals, which form of treatment will their hospital-employers dictate their employee-doctors choose? You can be sure it will be the less-expensive treatments.

 

(For more on this subject, stay tuned for Part II of this series on my next blog.)